Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EMN 2018 | New strategies for durable remission in MM

Niels van de Donk • 19 Apr 2018
EMN 2018
Multiple Myeloma Rare Diseases Smoldering Myeloma Antibodies Daratumumab
CASSIOPEIA

There are an increasing amount of promising targeted therapies being investigated for multiple myeloma (MM). In this interview, Niels van de Donk, MD, PhD, from VU University Medical Centre, Amsterdam, Netherlands, speaking from the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy, discusses techniques for progressing to durable tumor-free remission. Dr van de Donk describes the pros and cons of various antibody treatments, whilst highlighting the importance of using a tumor map for improving induction, consolidation and maintenance therapy.

More from Niels van de Donk

4:33
Cilta-cel elicits deep and durable responses in patients with multiple myeloma with early relapse
Niels van de Donk • 13 Dec 2021
2:42
Iberdomide plus dexamethasone for heavily pretreated multiple myeloma
Niels van de Donk • 13 Dec 2021
3:03
The future of CAR-T therapy for multiple myeloma
Niels van de Donk • 13 Dec 2021
1:45
Mechanisms of action of CD38 antibodies in myeloma
Niels van de Donk • 13 Dec 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals